单核细胞增生性李斯特菌作为肿瘤疫苗运送载体的研究进展  

Progress of Listeria monocytogenes as tumor vaccine vector

作　　者：段斐斐 殷月兰 康美琴 谈卫军 陶成武 潘志明 黄金林 焦新安 

机构地区：[1]扬州大学,江苏省人兽共患病重点实验室,江苏省动物主要疫病和人兽共患病防控协同创新中心,扬州225009

出　　处：《中国人兽共患病学报》2014年第7期743-746,752,共5页Chinese Journal of Zoonoses

基　　金：江苏省科技支撑计划(BE2012367);江苏省自然科学基金(BK2011446);国家自然科学基金(31101841);江苏高校优势学科建设工程项目资助~~

摘　　要：单核细胞增生性李斯特菌是一种兼性胞内寄生菌,能直接感染抗原递呈细胞,使所运送的外源抗原可以同时进入MHCⅠ类和MHCⅡ类抗原递呈途径,从而诱导强烈的CD+8T细胞和CD+4T细胞免疫应答。目前,减毒李斯特菌作为一种新型的活疫苗载体,在运送宫颈癌、黑色素瘤等肿瘤相关抗原方面业已取得较好的免疫保护效果,在抗肿瘤治疗中显示出诱人的前景。本文综述了单核细胞增生性李斯特菌的免疫应答特性及其作为治疗性肿瘤疫苗载体的相关研究进展。Listeriamonocytogenes is a facultative intracellular bacterium that enters professional antigen presenting cells , presents passenger antigens to the major histocompatibility complex class I and II pathways ,then elicits CD4^＋ and CD8^＋ T-cell-mediated immune responses .It was demonstrated that attenuated Listeriamonocytogenes as a novel live vaccine vector in delivering tumor antigens of cervical cancer and melanoma etc .,could induce strong protective immune response ,and shows effec-tive antitumor immunotherapeutics .This review discussed the characteristics of immune responses elicited by Listeria monocy-togenes ,and the progress of its antitumor immunotherapeutics as delivery vaccine vector .

关 键 词：单核细胞增生性李斯特菌 疫苗载体 肿瘤 

分 类 号：R378[医药卫生—病原生物学]